Dr. Torsten Neuefeind
Torsten founded Proteros based on the belief that structural biology services would become a key market requirement in the future of industrial Drug Discovery.
Torsten set up the company based on a McKinsey &Co awarded business plan and the experience of his PhD thesis in the lab of Nobel prize winner Prof. R. Huber at the Max-Planck Institute of Biochemistry, Munich as well as at Bayer AG. He set up the company structure, including high performance teams, a supervisory board and involvement of Prof. Huber as a co-founder and scientific advisor. He continues to manage the financing of the growth of the company in all stages and developed the business in Europe, US and Japan and made Proteros a renowned market leader in its segment, awarded as one of Bavaria’s best innovative growth companies.
Under Torsten’s guidance, the business has grown to serve most of the Top20 Big Pharma Companies, numerous midsize Pharma and more than 200 Biotech and virtual Biotech companies with a strong presence in the US, including a partnership with a US Venture Capital firm, resulting in a successful exit of a jointly funded company, worth several hundred million ‘Bio-Dollars’.
Proteros today is a premier provider of structure accelerated early Drug Discovery services, with a clear focus on scientific excellence and the most challenging drug targets and is a highly regarded brand in the community.
Torsten holds a degree in chemistry and a PhD with summa cum laude from the Technical University Munich including business courses e.g. from INSEAD. He serves on various Boards and is located in Munich.
Our Board Members
Prof. Eric P. Pâques
Eric P. Pâques is Non-Executive Chairman of the Supervisory Board of Proteros Biostructure GmbH (Munich, Germany) since 2014, chairman of the Board of Directors of Novadip Biosciences (Belgium) and Board member of Epics Therapeutics (Belgium) and of PL Bioscience (Germany) as well as of several academic and charity organizations. He was Independent Director of INC Research Inc., later Syneos Health, (USA), and Vice-Chairman of the Supervisory Board of the Grünenthal Group (Germany). He served more than 35 years in management positions in the pharmaceutical industry, thereof 20 years as General Manager / CEO of the Grünenthal Group. He is professor at the RWTH-Aachen University (Germany) and holds a Master degree and a PhD in Chemistry (University of Louvain, Belgium).
Daniel Spasic is a driven life science entrepreneur with 25 years in senior life science executive roles. He founded TFS International (TFS) in 1996, which became a world-leading midsized global clinical CRO. Under Daniel Spasic's leadership the business grew to $100 million in revenues employing 800+ professionals and serving 250 biopharma and medtech customers worldwide. Daniel Spasic’s expertise covers biopharma- and healthcare services, and he provides advice and guidance in areas such as; strategic positioning, growth enabling initiatives, partnership alliances, venture- and growth funding.
Caspar Graf Stauffenberg
Caspar Graf Stauffenberg is Managing Partner at Carlsquare, a M&A advisory company, where he heads the life sciences and health sector team. He studied Business Administration in Reutlingen (Germany) and London. Subsequently he has worked as project leader at Arthur D. Little in the business area Strategy and Organization and also as project leader Merger & Acquisitions at the Binding Group (today: Radeberger). Before he came to Carlsquare, he has been engaged as initially CFO and subsequently CEO for the MAP Medizin Technologie GmbH as well as CEO and Co-Founder of the Aequos Endoprothetik GmbH. Both such companies have been divested under his leadership.